In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, Themis Medicare has informed that it enclosed a copy of the press release titled - Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing.
The above information is a part of company’s filings submitted to BSE.